Trial site
Encore Medical Research LLC
Hollywood, Florida 33024, United StatesNot linked to an institution yet
- 18running trials
- 6closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 25 trials
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Completed6 trials
- Recruiting6 trials
- Not yet recruiting5 trials
- Lead sponsor
- Novo Nordisk A/S20 trials
- Amgen2 trials
- Incyte Corporation1 trial
- Insud Pharma1 trial
Running trials
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
NCT07931547· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT07931495· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
NCT07668414· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
NCT07668388· Phase 2· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021· Phase 2· Novo Nordisk A/S· Source
Active, not recruiting
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954· Phase 2· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698· Phase 2· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445· Phase 3· Incyte Corporation· Source
Active, not recruiting
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
NCT05303636· Phase 4· Insud Pharma· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error